Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement. Pediatr Blood Cancer 2013 Mar;60(3):500-2

Date

11/07/2012

Pubmed ID

23129109

Pubmed Central ID

PMC4461026

DOI

10.1002/pbc.24383

Scopus ID

2-s2.0-84872441623   4 Citations

Abstract

We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post-treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treated for an adenoidectomy with purified fibrinogen concentrate (RiaSTAP®) at a dose of 70 mg/kg. A discrepancy in post-treatment fibrinogen activity was observed between the hospital and reference laboratories. Investigation revealed differences in laboratory assay and calibration methods. Fibrinogen concentrate may be a treatment option for patients with dysfibrinogenemia, but accurate laboratory technique is critical for fibrinogen measurement.

Author List

Franzblau EB, Punzalan RC, Friedman KD, Roy A, Bilen O, Flood VH

Authors

Veronica H. Flood MD Professor in the Pediatrics department at Medical College of Wisconsin
Kenneth D. Friedman MD Professor in the Medicine department at Medical College of Wisconsin
Rowena C. Punzalan MD Associate Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Afibrinogenemia
Fibrinogen
Hematologic Tests
Humans
Laboratories
Laboratories, Hospital
Male
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a